Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
about
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
description
clinical trial
@en
klinisch onderzoek
@nl
name
Neoadjuvant CCRT With Gemcitab ...... e Resectable Pancreatic Cancer
@en
type
label
Neoadjuvant CCRT With Gemcitab ...... e Resectable Pancreatic Cancer
@en
prefLabel
Neoadjuvant CCRT With Gemcitab ...... e Resectable Pancreatic Cancer
@en
P1476
Neoadjuvant CCRT With Gemcitab ...... e Resectable Pancreatic Cancer
@en
P3098
NCT03572400
P580
2018-11-29T00:00:00Z
P582
2021-11-30T00:00:00Z